India's First Covid nasal spray

The FabiSpray intended for high-risk adults prevents the virus from reaching the lungs.

India's First Covid nasal spray
Source: Twitter

The FabiSpray Nitric Oxide Nasal Spray developed in conjunction with SaNOtize Research & Development Corp., a Canadian pharmaceutical firm with  Glenmark pharmaceuticals just completed its phase 3 multicenter, double-blind, parallel-arm research with over 300 Indian patients, which was recently finished.

Adult patients who were not hospitalized and were randomly allocated during a 72-hour window of symptom onset were intensively monitored. Individuals with a high risk of disease development, including as nonvaccinated patients, patients in the middle and older age groups, and patients with comorbidities, were also included in the study.